These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20024547)

  • 21. Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma.
    Barber A; Zhang T; Megli CJ; Wu J; Meehan KR; Sentman CL
    Exp Hematol; 2008 Oct; 36(10):1318-28. PubMed ID: 18599182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxidative stress mediates a reduced expression of the activating receptor NKG2D in NK cells from end-stage renal disease patients.
    Peraldi MN; Berrou J; Dulphy N; Seidowsky A; Haas P; Boissel N; Metivier F; Randoux C; Kossari N; Guérin A; Geffroy S; Delavaud G; Marin-Esteban V; Glotz D; Charron D; Toubert A
    J Immunol; 2009 Feb; 182(3):1696-705. PubMed ID: 19155520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Four novel ULBP splice variants are ligands for human NKG2D.
    Cao W; Xi X; Wang Z; Dong L; Hao Z; Cui L; Ma C; He W
    Int Immunol; 2008 Aug; 20(8):981-91. PubMed ID: 18544572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quercetin enhances susceptibility to NK cell-mediated lysis of tumor cells through induction of NKG2D ligands and suppression of HSP70.
    Bae JH; Kim JY; Kim MJ; Chang SH; Park YS; Son CH; Park SJ; Chung JS; Lee EY; Kim SH; Kang CD
    J Immunother; 2010 May; 33(4):391-401. PubMed ID: 20386467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA demethylation and histone H3K9 acetylation determine the active transcription of the NKG2D gene in human CD8+ T and NK cells.
    Fernández-Sánchez A; Baragaño Raneros A; Carvajal Palao R; Sanz AB; Ortiz A; Ortega F; Suárez-Álvarez B; López-Larrea C
    Epigenetics; 2013 Jan; 8(1):66-78. PubMed ID: 23235109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
    Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
    J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
    Wu L; Parton A; Lu L; Adams M; Schafer P; Bartlett JB
    Cancer Immunol Immunother; 2011 Jan; 60(1):61-73. PubMed ID: 20848094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.
    Doubrovina ES; Doubrovin MM; Vider E; Sisson RB; O'Reilly RJ; Dupont B; Vyas YM
    J Immunol; 2003 Dec; 171(12):6891-9. PubMed ID: 14662896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Importance of NKG2D-NKG2D ligands interaction for cytolytic activity of natural killer cell.
    Bae DS; Hwang YK; Lee JK
    Cell Immunol; 2012; 276(1-2):122-7. PubMed ID: 22613008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications.
    Chitadze G; Bhat J; Lettau M; Janssen O; Kabelitz D
    Scand J Immunol; 2013 Aug; 78(2):120-9. PubMed ID: 23679194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8
    Vadstrup K; Galsgaard ED; Jensen H; Lanier LL; Ryan JC; Chen SY; Nolan GP; Vester-Andersen MK; Pedersen JS; Gerwien J; Jensen T; Bendtsen F
    Exp Mol Pathol; 2017 Aug; 103(1):56-70. PubMed ID: 28684217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of NKG2D haplotypes on the cell-surface expression of NKG2D protein on natural killer and CD8 T cells of peripheral blood among atomic-bomb survivors.
    Imai K; Hayashi T; Yamaoka M; Kajimura J; Yoshida K; Kusunoki Y; Nakachi K
    Hum Immunol; 2012 Jun; 73(6):686-91. PubMed ID: 22507622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
    Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
    Front Immunol; 2020; 11():40. PubMed ID: 32082316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.
    Carbone E; Neri P; Mesuraca M; Fulciniti MT; Otsuki T; Pende D; Groh V; Spies T; Pollio G; Cosman D; Catalano L; Tassone P; Rotoli B; Venuta S
    Blood; 2005 Jan; 105(1):251-8. PubMed ID: 15328155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
    Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
    Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1 ?
    Giuliani E; Vassena L; Cerboni C; Doria M
    Curr Drug Targets; 2016; 17(1):54-64. PubMed ID: 26122035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells.
    Burgess SJ; Marusina AI; Pathmanathan I; Borrego F; Coligan JE
    J Immunol; 2006 Feb; 176(3):1490-7. PubMed ID: 16424177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T cells expressing the activating NK-cell receptors KIR2DS4, NKG2C and NKG2D are elevated in paroxysmal nocturnal hemoglobinuria and cytotoxic toward hematopoietic progenitor cell lines.
    van Bijnen ST; Withaar M; Preijers F; van der Meer A; de Witte T; Muus P; Dolstra H
    Exp Hematol; 2011 Jul; 39(7):751-62.e1-3. PubMed ID: 21554925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
    Di Modica M; Sfondrini L; Regondi V; Varchetta S; Oliviero B; Mariani G; Bianchi GV; Generali D; Balsari A; Triulzi T; Tagliabue E
    Oncotarget; 2016 Jan; 7(1):255-65. PubMed ID: 26595802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential expression of ligands for NKG2D and DNAM-1 receptors by epithelial ovarian cancer-derived exosomes and its influence on NK cell cytotoxicity.
    Labani-Motlagh A; Israelsson P; Ottander U; Lundin E; Nagaev I; Nagaeva O; Dehlin E; Baranov V; Mincheva-Nilsson L
    Tumour Biol; 2016 Apr; 37(4):5455-66. PubMed ID: 26563374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.